ZYTIGA® Receives Positive Regulatory Recommendation in the European ... Business Wire (press release) Study COU-AA-302 is a Phase III, international, randomised, double-blind, placebo controlled study which evaluated ZYTIGA® plus prednisone/prednisolone compared to placebo plus prednisone/prednisolone in 1,088 asymptomatic or mildly symptomatic ... |
